English HTA OKs AbbVie’s Bispecific Antibody Tepkliny for DLBCL After Initial Refusal

Patients in England with relapsed or refractory diffuse large B-cell lymphoma will have another treatment option after the health technology appraisal institute NICE recommended AbbVie’s bispecific antibody Tepkinly for funding on the National Health Service . The product is also undergoing a benefit assessment in Germany.